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Summary
Osteogenesis imperfecta is an inherited connective tissue
disorder with wide phenotypic and molecular heterogen-
eity. A common issue associated with the molecular ab-
normality is a disturbance in bone matrix synthesis and
homeostasis inducing bone fragility. In very early life, this
can lead to multiple fractures and progressive bone de-
formities, including long bone bowing and scoliosis. Mul-
tidisciplinary management improves quality of life for pa-
tients with osteogenesis imperfecta. It consists of physical
therapy, medical treatment and orthopaedic surgery as ne-
cessary. Medical treatment consists of bone-remodelling
drug therapy. Bisphosphonates are widely used in the treat-
ment of moderate to severe osteogenesis imperfecta, from
infancy to adulthood. Other more recent drug therapies
include teriparatide and denosumab. All these therapies
target the symptoms and have effects on the mechanical
properties of bone due to modification of bone remodel-
ling, therefore influencing skeletal outcome and orthopaed-
ic surgery. Innovative therapies, such as progenitor and
mesenchymal stem cell transplantation, targeting the spe-
cific altered pathway rather than the symptoms, are in the
process of development.
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Introduction
Osteogenesis imperfecta (OI), commonly referred to as
brittle bone disease, is a rare genetic disease with an in-
cidence of 1/15 000–20 000. In 1979, Sillence et al. pub-
lished the first description of four OI groups (OI I–IV)
(table 1) with specific genetic inheritance, based on spe-
cific phenotypes (clinical, radiographic and pedigree fea-
tures) [1]. In 1983, Chu et al. reported the presence of an
internal deletion in a collagen gene (COL1A1) [2] implic-
ated in OI. Altogether, several autosomal mutations in the
COL1A1 and COL1A2 genes, coding for the alpha-1 and al-
pha-2 chains of collagen type I, were discovered in the four
OI groups known at that time. In 2004, Glorieux and Rauch
described three new OI groups, with specific clinical char-
acteristics and without genetic modification in COL1A1 or
COL1A2 (OI V–VII) [3]. Barnes et al. described the first
non-COL1A1/2 autosomal recessive mutation in 2006 [4].
Since this time, multiple new genes implicated in collagen
expression, structure and function have been discovered,
elaborating a more extensive genetic classification. The
majority of OI patients have autosomal dominant mutations
affecting type I collagen genes (COL1A1, COL1A2), res-
ulting in reduced production or abnormal type I collagen
formation and thus leading to bone fragility (fig. 1). Rare
autosomal recessive or X-linked mutations (6–8% of all OI
cases) have been identified, involving procollagen modific-
ations, collagen fibre maturation, and bone formation and
mineralisation [5]. In the 2015 revision of the nosology
and classification of genetic skeletal disorders, the Sillence
classification based on phenotype is still used [6], since the
diagnosis, classification and severity assessment of OI is
based on the clinical phenotype over time [7].
Classification
Since the Sillence description of four OI types (OI I–IV),
more than 1500 dominant mutations in COL1A1/2 genes
have been identified. These mutations alter the structure or
the quantity of collagen type I and lead to skeletal pheno-
types ranging from subclinical to lethal OI [8]. Recessive
mutations in collagen-related genes, where the related pro-
teins interact with type I collagen, cause lethal to moderate
OI phenotypes. It became, therefore, impossible to main-
tain a close correlation between the molecular genetic basis
and the Sillence OI types. In 2010, the Nosology Group
of International Skeletal Dysplasia Society decided to use
the Sillence classification as the prototypic and universal
way to classify the degree of severity in OI (INCDS clas-
sification). They separated the Sillence classification from
molecular reference, and listed separately many genes in-
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volved in OI [9]. At this time, arabic numbers instead of ro-
man numerals were used for types of OI, to emphasise the
phenotypic aspect, since roman numbers have been used
to classify new genetic mutations [7]. In 2015, the revised
INCDS classification was still associated with the Sillence
classification, being phenotypically rather than molecularly
based. OI type 5 was introduced into the classification as it
is radiologically phenotypically distinguishable from types
1–4.
Therefore, despite the multiplicity of new genes discovered
in the field of OI, genetic classification (table 2) is not cur-
rently used in clinical practice, and the phenotype classific-
ation is still the rule (table 3) [6]. Concomitantly with the
new INCDS OI classification, universal criteria to classify
the degree of severity of OI were needed. Van Dijk and Sil-
lence proposed a severity grading scale (table 4) [7]. This
relies on clinical and historical data, overall skeletal con-
dition with fracture timing (prenatal/prepubertal) and fre-
quency, bone densitometry, mobility and ambulatory level.
It allows comprehension of the course of the disease for pa-
tients, highlights the treatment possibilities (surgical, phar-
macological and conservative) and helps the physician to
evaluate therapy. The grade of severity of the disease is
based on phenotype observations and OI is clinically
graded from mild to extremely severe (table 4). This scale
has been already used in a multicentre study [10]. Possible
treatment has been included by the scale authors. The scale
is still under validation in specialised centres, but import-
antly gives a wide overview of the OI severity spectrum.
Table 1: 1979 Sillence classification of osteogenesis imperfecta.
OI Type Inheritance Features
I AD Osseous fragility (variable)
Adulthood hearing loss
Blue sclerae
II AD, AR Extremely severe osseous fragility
Perinatally lethal
III AR Moderate to severe osseous fragility
Normal sclerae
Severe deformity of long bones and spine
Variable clinical and radiographic phenotypes
IV AD, AR Osseous fragility
Generally normal sclerae
Severe deformity of long bones and spine
AD = autosomal dominant; AR = autosomal recessive; OI = osteogenesis imperfecta
Table 2: Genetic and molecular classification of osteogenesis imperfecta.
Molecular pathway Gene Heredity Sillence
phenotype
Features
COL1A1 AD I, II, III, IVCollagen I structural defect or
haploinsufficiency COL1A2 AD I, II, III, IV
Blue/grey/normal sclerae
Hyperlaxity
Hypoaccousia
Dentinogenesis imperfecta
CRTAP AR II, III, IV (VII)
LEPREI AR II, III (VIII)
Prolyl-3-hydroxylase complex
PPIB AR II, III, IV (IX)
Lysyl-hydroxylase telopeptide PLOD2 AR III Pterygium
Congenital articular contractures (Bruck syndrome type 2)
FKBP10 AR III, IV (XI) Eventual congenital articular contracture (Bruck syndrome type 1)Collagen chaperone
SERPINH1 AAR II, III (X) Blue sclerae
Dentinogenesis imperfecta
Collagen type I maturation BMP1 AR XIII Elevated bone density
Blue sclerae
SERPINF1 AR III, IV (VI) Progressive low bone mass
Poor response to bisphosphonates
Good response to anti-RANKL antibody
SP7 AR III (XII) Delayed dental eruption
LRP5 AR III, IV Visual impairment (osteoporosis-pseudoglioma syndrome)
WNT1 AR III, IV (XV) Progressive evolution
Poor response to bisphosphonates
TMEM38B AR III (XIV)
Osseous homeostasis and
formation, bone mass regulation
CREB3L1 AR II, III
IFITM5 AD V Hypertrophic callous
Interosseous membrane calcifications
Sclerotic metaphyseal band
Unknown function
PLS3 X-linked I Early osteoporosis for heterozygous female
Type I OI for hemizygous males
AD = autosomal dominant; AR = autosomal recessive; OI = osteogenesis imperfecta; RANKL = receptor activator of nuclear factor-κB ligand
Roman numbers are used for Sillence types as this concerns the genetic classification (cf text)
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Clinical findings
OI diagnosis is based on clinical and radiographic findings.
OI types 1, 4 and 5 are phenotypes with mild to moderate
severity, while OI types 2 and 3 are severe to extremely
severe phenotypes. OI type 1 is the non-deforming form
with blue sclerae (fig. 2); OI type 4 is a common variable
form with normal sclerae; OI type 5 is a form with inter-
osseous membrane calcification. OI type 3 is a severe, pro-
gressively deforming form and OI type 2 is an extremely
severe, perinatally lethal form.
Clinical features are directly linked to the fact that OI
is a generalised, predominantly collagen-tissue disorder.
Depending of the causative mutation, the primary structural
defect of type I collagen, insufficient collagen quantity,
and the posttranslational modification, folding, intracellu-
lar transport or matrix incorporation of abnormal colla-
Figure 1
Collagen type I biosynthesis and bone formation. Collagen I is a
triple helix with two alpha-1 and one alpha-2 chains encoded by
COL1A1 and COL1A2 genes. After translation, the pro-alpha-
chains are translocated in the rough endoplasmic reticulum (rER)
where posttranslational modifications occur (1)(2). The chains are
folded in a triple helix, composed of two alpha-1 and one alpha-2
chains (2). These steps are, among others, under the control of
CRTAP, LEPRE 1, PPIB and FKBP10 genes. The procollagen is
then further modified during the transport to the Golgi apparatus
(influence of SERPINH1, PLOD2 and FKBP10 genes). The
procollagen is then delivered into the extracellular matrix by
exocytosis. There, cleavage and removal of the pro-peptides N and
C results in collagen I formation (3). Crosslinking of collagen
molecules leads to fibril formation. Assembly of multiple collagen
type 1 fibrils leads to collagen fibres which are constituents of bone
(4). Osteoblasts produce a collagen-rich extracellular matrix that
will be mineralised and osteoclasts degrade bone. Bone formation
and resorption is regulated through cross-talk between osteoblasts
and osteoclasts. In osteogenesis imperfecta, altered quality and/or
quantity of collagen I formation, altered cross-talk between
osteoblasts and osteoblasts, leads to a defect in bone formation.
Bisphosphonates concentrate in the mineralised osseous matrix
where they inhibit bone resorption by osteoclasts.
gen lead to an abnormal bone matrix and reduced bone
strength, with resulting bone fragility, higher fracture risk,
bone deformity and linear growth deficiency (fig. 2). Iter-
ative fractures with mild trauma are then observed even
at a young age, as well as joint laxity and weak muscle
tone. Progressive skeletal deformities including bowing de-
formities of long bones, scoliosis, kyphosis, basilar impres-
sion, and chest wall deformities such as pectus excavatus or
carinatus (i.e. barrel chest) are possible. Depending on OI
severity, patients present variable degrees of short stature,
OI type 1 having none to mild linear growth deficiency,
OI type 4 having mild to moderate, and OI type 3 with
very severe [11, 12]. Ambulation and mobility is limited in
severely affected patients. Radiographic characteristics in-
clude osteopenia, bowed long bones, thin and under-tubu-
larised long bones, gracilis ribs, vertebral compression and
narrow thoracic apex (fig. 2 radiograph) [13]. Extraskeletal
manifestations include blue sclerae, easy bruising owing to
cutaneous and vascular fragility, progressive hearing loss in
young adulthood, variable progressive impairment of pul-
monary function and dentinogenesis imperfecta (fig. 2) [5,
7, 14]. Compared with healthy controls, OI patients seem
to have a slightly increased risk of developing cardiac valv-
ular disease, but more studies are needed to support this hy-
pothesis [15]. Differential diagnosis is sometimes difficult
between the mild forms of OI and of child abuse in chil-
dren, or between OI and primary osteoporosis in older pa-
tients. Distinction between OI and child abuse (also called
nonaccidental injury: NAI) is mainly based on history, clin-
ical examination and radiography. Trauma description
should be consistent with the clinical and radiological find-
ings. OI and NAI children may have multiple bruises and
contusions, but, despite a tendency for bruising capacity
in OI, multiple and unusually localised hematomas are not
the rule and should raise the suspicion of NAI. Radiolo-
gical features of NAI and OI include multiple fractures of
various ages, diaphyseal and vertebral fractures, anterior
and lateral rib fractures, and hyperplastic callus formation.
NAI children do not have osteopenia, long bone or skull
deformities. Children with OI do not usually have typical
corner metaphyseal lesions, spinous processes or posterior
rib fractures. Multiple fractures in a child with OI type 1
Figure 2
Characteristics of osteogenesis imperfecta (OI) types 1–5,
illustrating morphological features for each stage.
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are uncommon and NAI cannot be ruled out in favour of OI
[16].
Clinical management
Amelioration of mobility, self-care, functional independen-
ce and better quality of life at an adult age are the main
goals of the proposed therapeutic approaches. These treat-
ment plans are based on a multidisciplinary approach,
which includes medical management of bone-remodelling
drug therapy; orthopaedic treatment (conservative or sur-
gical) for fractures and deformity stabilisation; rehabilita-
tion for muscular strengthening and movement or a walk-
ing strategy. The multidisciplinary approach has led to bet-
ter functional outcomes for patients but its practical ap-
plication depends nevertheless on the degree of OI severity
[17–19].
As shown in table 3, prognosis and management are
strongly related to the type of OI. It is noteworthy that
severity is highly variable even within OI families, and
treatment is guided by the severity rather than the type of
OI. In mild non-deforming OI, diagnosis is usually accom-
plished during childhood or early puberty, when fractures
for minor trauma or bone pain in association with low bone
mineral density occur. These patients rarely develop long
bone deformities. Surgery is rarely necessary and is more
dependent on the fracture type than the disease itself. Frac-
ture healing is normal in OI, and if no internal fixation
is needed, cast immobilisation duration is the same as for
healthy children. Casts should not be maintained more than
necessary and mobilisation should be as soon as possible
to minimise secondary bone fragility and mobility diminu-
tion.
In moderate or severe OI, very early fractures and/or bone
deformities occur. Early correction of long bone deform-
ities and bone fragility stabilisation with intramedullary
rodding has been associated with better motor status im-
provement and ambulation in severe OI [20, 21]. Plates
are contraindicated as all the stress could be transferred
to the plate and thus the underlying bone would become
less strong, with subsequent fractures at the plate extremit-
ies. Telescopic growing rods can be used and have been
associated with a lower rate of re-rodding [18]. Together
with surgery, moderate and severe forms of OI benefit from
specific drug therapies. Generally, long bone deformations,
vertebral fractures and frequent fractures should raise the
possibility of bisphosphonate treatment. Bisphosphonate
treatment is the most frequently used. Bisphosphonate con-
centrates in the mineralised osseous matrix where it in-
hibits bone resorption by osteoclasts (fig. 1) and corres-
pondingly favours an increase in bone mineral density.
Prior to starting a bisphosphonate it is essential to maxim-
ise calcium and vitamin D supplementation, as sufficient
concentrations are necessary for an optimal treatment re-
sponse [22]. Bisphosphonate can be administered to chil-
dren younger than 24 months old with net results on de-
creased fractures rates and increased patient mobility [23,
24], but without reversing the fracture rate or scoliosis
evolution of severe OI to a mild OI situation [25]. Studies
have shown a diminished fracture risk for children without
alteration of linear growth [10, 23, 24, 26, 27]. Augmenta-
tion of cortical thickness and vertebral height, and diminu-
tion of musculoskeletal pain and fatigue are described as
results of bisphosphonate treatment [28]. Bisphosphonates
have a half-life in bone of more than a decade, and at the
end of the treatment they still have an impact on bone
modelling and quality [29, 30]. Bisphosphonates do not
delay bone healing after fracture, but it is recommended to
avoid sawing techniques for surgical osteotomies as heat-
ing may alter bone consolidation; there is a generally ac-
cepted consensus to keep an interval of 2–4 months after
surgery free of bisphosphonate infusions [31, 32]. Bisphos-
phonate treatments have, however, raised some concerns
about atypical femoral stress fractures due to suppression
of remodelling and the secondary loss of bone elasticity
on the long bone mechanical stress zone. Awareness about
their benefits and risks, limited duration and a bone mech-
anical axis as physiological as possible seem to be the bet-
ter guarantee against these atypical fracture risks [33–36].
Therefore, although they are commonly used, due to poten-
tial risks, the decision to use bisphosphonate therapies must
still be individualised.
Despite the amelioration of bone density and fracture risk,
patients under bisphosphonate treatment still have long
bone fractures and progressive scoliosis, and these are still
of concern, even in mild forms of OI [37]. Scoliosis is the
second major orthopaedic concern in OI, with a prevalence
ranging from 39% to 88% [38]. In mild OI the majority are
self-limited, but in moderate to severe OI evolution can be
severe, even with bisphosphonate treatment. This leads to
the hypothesis that, although deformity from repetitive ver-
tebral fractures, and altered bone quantity and quality are
commonly reported as contributory factors, ligament lax-
ity and muscle weakness are also important factors in the
pathophysiology of scoliosis in OI [39]. Bracing is inef-
fective and contraindicated because of secondary chest and
rib deformities [40, 41]. Arthrodesis with posterior spin-
al instrumentation is needed for a progressive curve reach-
ing 50° to stop curve progression and prevent pulmonary
impairment; types 3 and 4 OI are mainly concerned. The
arthrodesis may be preceded by a period of cranial halo
traction for very severe curves [42]. Other spinal deform-
ities such as thoracolombar kyphosis, lumbosacral spon-
dylolisthesis, and basilar invagination at the craniocervical
junction are frequently seen and may necessitate interven-
tions [40].
In severe OI, upper limb long bone deformities with severe
bowing and radial head dislocation are frequent and very
disabling. Surgical correction is indicated in order to re-
lieve pain if present, and when functional abilities are af-
fected (self-care, wheelchair autonomous hand-rolling)
[43, 44]. Pelvic and hip progressive deformations occur
in severe OI: coxa vara has a very negative effect on the
functional status of the patient and hip correction inter-
ventions may be necessary [45, 46]; severe acetabular pro-
trusion induces hip stiffness and can have some urinary
or gastrointestinal tract implications that, however, rarely
need intervention. Report of one case requiring colostomy,
femoral traction and pelvic osteotomy to release intestinal
compression does exist [47, 48].
Besides drug therapy and orthopaedic management,
physiotherapy is key in OI management. For many years,
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rehabilitation programmes have been proposed for OI pa-
tients and have gained in efficacy since the introduction
of bisphosphonates into OI management [49]. In children,
gross motor development acquisition, safety in active
movement and minimisation of the development of early
complications are the predominant targets. Rehabilitation
strategies are individualised depending on clinical assess-
ment and function [50]. OI type and total muscle strength
being strongly associated with ambulation, particular atten-
tion to muscle training and maintenance is warranted [51,
52]. Indeed, regular physical activity is important in OI
management. The type of activity is directly linked to the
type of OI. Compared with healthy children, OI type 1 chil-
dren have muscle weakness independent of a hypoactive
activity level [52–54].
Recent medical treatment options
Despite the use of bisphosphonates, several potential inter-
esting alternatives could be used in the drug therapy for OI.
Teriparatide (derived from recombinant human parathyroid
hormone) has been shown to stimulate bone formation and
has a beneficial effect on bone mineral density, but has no
impact on the fracture risk in this population (insufficient
data). There is some evidence that teriparatide could ameli-
orate healing of atypical femoral stress fracture in adults
[33], but no evaluation has been reported of teriparatide use
in children with OI and there is concern about a neoplastic
risk in children [55, 56].
Denosumab (an anti-RANK [receptor activator of nuclear
factor-κB] ligand antibody) inhibits osteoclast formation
and bone resorption. It has been approved during the last
decade for the treatment for osteoporosis in postmenopaus-
al women and recently for men [57]. In children, 2-year
periods of treatment in four OI type VI patients have been
reported. OI type VI bone is characterised by an increased
amount of non-mineralised osteoid. Bisphosphonate binds
to mineralised bone surface and lack of bisphosphonate
binding is thought to be one of the reasons for a low re-
sponse to bisphosphonate treatment in OI type VI. During
the treatment period no severe side effects were noticed
but slight hypocalcaemia suggested that calcium supple-
mentation should be given. Denosumab is degraded within
3–4 months and has no long-term accumulation such as bi-
sphosphonates have. During the observed period, there was
no impact on longitudinal bone growth and denosumab led
to an increase of bone mineral density and mobility, and a
marked and reversible suppression of bone resorption [58,
59]. However, no long-term data exist in children and fur-
ther studies are needed to evaluate the long-term safety and
benefits.
A new treatment, an antisclerostin antibody, is in develop-
ment in osteoporosis and has shown an interesting benefit
in OI. Already tested in OI mice, the antisclerostin antibody
is promising through its mechanism of action: it decouples
bone formation and resorption in favour of bone formation,
with an important gain in bone quantity [60]. Human stud-
ies in OI are ongoing.
Table 3: Current modified phenotypic Sillence classification of osteogenesis imperfecta from the Nosology Group of the International Skeletal Dysplasia Society (adapted
from Bonafé L, et al. Nosology and Classification of Genetic Skeletal disorders: 2015 Revision. Am J Med Genet A. 2015;167A(12):2869-92 9999A:1–24).
OI Type Inheritance Features
1 AD Non-deforming form
Osseous fragility
Presenile hearing loss
Blue sclerae
2 AD, AR Perinatal lethal form
Extremely severe osseous fragility
3 AD, AR Progressively deforming form
Moderate to severe osseous fragility
4 AD, AR Moderate form
Generally normal sclerae
5 AD, AR Calcification of the interosseous membrane and/or hypertrophic callus
AD = autosomal dominant; AR = autosomal recessive; OI = osteogenesis imperfecta
Table 4: Pre- and postnatal severity grading scale (adapted from Van Dijk FS, Sillence DO. Osteogenesis imperfecta: Clinical diagnosis, nomenclature and severity
assessment. Am J Med Genet A. 2014;164A:1470–81).
Intrauterine (ultrasound at
20 weeks of pregnancy)
Growth velocity and
height
Intrinsic bone
deformations
Annualised prepubertal
# rate
Locomotion status
Mild OI No #, No long bone
deformities
Normal or near normal None ≤1 Ambulant
Moderate OI Rare fetal long bone # or
bowing
Decreased Anterior femoral and tibial
bowing
>1 Ambulant
Severe OI Long bones shortening
Long bone # and bowing
Rib #
Severely decreased Long bone and spine
progressive deformity
>3 Wheel-chair dependent
Extremely severe OI Long bone shortening
Long bone # and bowing
Rib #
↓Mineralisation
Multiple long bone fractures at birth, all vertebrae are crushed, small thorax, respiratory distress
Perinatally lethal course
# = fracture; OI = osteogenesis imperfecta
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Innovative therapies for a cure for
osteogenesis imperfecta
The current treatments and new drug therapies proposed
for OI target only the symptoms and there is a definite need
to develop a solution that could lead to a cure for OI. Pro-
gress in genetic or molecular diagnosis have led to a bet-
ter understanding of the physiopathology of OI, permitting,
for example, a specific molecular treatment for OI type VI
with denosumab [58, 61], and potentially could open the
door to more appropriate treatments, targeting the specif-
ic altered pathway [62]. Gene targeting in mesenchymal
stem cells from OI individuals has been possible in mice,
with resultant normal collagen and bone production in vivo.
[63, 64] Gene silencing using small interfering RNAs has
been possible in vitro in human bone derived cells. There
is still necessity for clinical trials of gene therapy. Preclin-
ical studies using different in-vivo models [65–67] suggest
some potential effect with bone marrow transplantation in
treating OI and are consistent with clinical transplantation
of mesenchymal stem cells or whole bone marrow in chil-
dren with severe forms of OI. The first clinical trial in-
volved the treatment of children suffering from OI with
allogeneic bone marrow-derived mesenchymal cells from
HLA-identical or single-antigen-mismatched siblings. An
increase in bone condition (increase in growth velocity and
bone mineral content, reduced frequency of bone fracture)
during 6 months following the infusion was observed [68].
A further study by the same group involving five OI chil-
dren was performed (again with HLA-compatible donors).
It was mentioned that, ideally, therapy for OI should be
directed toward improving bone strength by improving the
structural integrity of collagen and thereby the quality of
the bone. The positive effect of the first study was still ob-
served after 36 months, while a decrease in efficacy com-
pared with the initial 6 months was also observed. The
working hypothesis of the study was that bone marrow
transplants contain mesenchymal precursor cells that can
engraft in the skeleton and generate osteoblasts capable of
modifying abnormal bone structure. The cell engraftment
in the bone marrow is then a key aspect for a successful
and, hopefully, long-lasting treatment of OI with a cell ther-
apy strategy.
As a result of the promising results of the previous clinical
trials, a study involving the injection of mesenchymal stem
cells obtained from the same donors as those used for bone
marrow transplantation was performed. It was found that
allogeneic bone marrow-derived mesenchymal cells could
engraft in bone, marrow stroma and skin without the re-
quirement for preparative chemotherapy, and then produce
clinically measurable benefits. However, it was also sug-
gested that a beneficial effect from transplanted whole mar-
row might not be available from infusions of isolated donor
mesenchymal stem cells. It is proposed that other cell types
should be used [69]. An additional study was performed
on a single human fetus presenting an OI disorder. Allo-
geneic fetal mesenchymal stem cells were transplanted in
utero, and the cells were shown to engraft and differentiate
into bone even when the recipient was immunocompetent
and HLA-incompatible. However, very low engraftment
(0.3%) could still be demonstrated in bone at 9 months
of age [70]. Ideal cell types to be engrafted could include
bone marrow, mesenchymal stem cells from bone marrow
or adipose tissue, preosteoblasts and fetal bone cells (ge-
netically modified or not). The technical requirements for
obtaining and expanding each of these cell types vary con-
siderably and should be taken into consideration. Indeed,
if cells can be expanded easily to very large numbers and
stored in liquid nitrogen with high survival, the cell source
will perhaps be more dependable for implantation. Mesen-
chymal cells are known for low viability upon engraftment
and techniques to assure increased stability of cell sources
are imperative. Fetal bone cells have been evaluated for
therapeutic use since they can be expanded from one small
tissue fragment to develop a clinically dedicated cell bank
capable of stocking cells for hundreds of thousands of treat-
ments. These cells have the advantages of a high prolifera-
tion rate and early mineralisation and, unlike mesenchymal
cells, are already differentiated and dedicated to bone form-
ation without dedifferentiation to other cell types. Overall,
they may provide a stable cell source for therapeutic use in
the future, potentially in all types of OI [71, 72].
Altogether, the clinical studies to date suggest promising
beneficial effects of cell transplantation in OI even if stat-
istical significance of the reported studies was often lack-
ing owing to the small number of patients involved in each
study. The delivery methods and cell choice, as well as the
question of the role and the side effects of cell chimerism,
have to be addressed in order to improve long-lasting ef-
fects of cell therapies in OI.
Conclusion
There is currently no completely satisfactory treatment for
OI, and any treatments either altering bone resorption or
stimulating bone formation have an impact on the mech-
anical properties of bone. Bisphosphonates are an adjuvant
treatment to intramedullary rodding and other surgical pro-
cedures, but concern about properties of bone microarchi-
tecture remodelling capacities persists. Bone remodelling
with future cell therapies may be promising in OI treat-
ment.
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Figures (large format)
Figure 1
Collagen type I biosynthesis and bone formation. Collagen I is a triple helix with two alpha-1 and one alpha-2 chains encoded by COL1A1 and
COL1A2 genes. After translation, the pro-alpha-chains are translocated in the rough endoplasmic reticulum (rER) where posttranslational
modifications occur (1)(2). The chains are folded in a triple helix, composed of two alpha-1 and one alpha-2 chains (2). These steps are, among
others, under the control of CRTAP, LEPRE 1, PPIB and FKBP10 genes. The procollagen is then further modified during the transport to the
Golgi apparatus (influence of SERPINH1, PLOD2 and FKBP10 genes). The procollagen is then delivered into the extracellular matrix by
exocytosis. There, cleavage and removal of the pro-peptides N and C results in collagen I formation (3). Crosslinking of collagen molecules
leads to fibril formation. Assembly of multiple collagen type 1 fibrils leads to collagen fibres which are constituents of bone (4). Osteoblasts
produce a collagen-rich extracellular matrix that will be mineralised and osteoclasts degrade bone. Bone formation and resorption is regulated
through cross-talk between osteoblasts and osteoclasts. In osteogenesis imperfecta, altered quality and/or quantity of collagen I formation,
altered cross-talk between osteoblasts and osteoblasts, leads to a defect in bone formation. Bisphosphonates concentrate in the mineralised
osseous matrix where they inhibit bone resorption by osteoclasts.
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Figure 2
Characteristics of osteogenesis imperfecta (OI) types 1–5, illustrating morphological features for each stage.
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